These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34186055)
21. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Nassiri F; Mamatjan Y; Suppiah S; Badhiwala JH; Mansouri S; Karimi S; Saarela O; Poisson L; Gepfner-Tuma I; Schittenhelm J; Ng HK; Noushmehr H; Harter P; Baumgarten P; Weller M; Preusser M; Herold-Mende C; Tatagiba M; Tabatabai G; Sahm F; von Deimling A; ; Zadeh G; Aldape KD Neuro Oncol; 2019 Jul; 21(7):901-910. PubMed ID: 31158293 [TBL] [Abstract][Full Text] [Related]
22. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720 [TBL] [Abstract][Full Text] [Related]
23. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival. Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894 [TBL] [Abstract][Full Text] [Related]
24. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Korshunov A; Shishkina L; Golanov A Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057 [TBL] [Abstract][Full Text] [Related]
25. Analysis of the role of hMLH1 hypermethylation and microsatellite instability in meningioma progression. Chen MN; Wang P; Zhang J; Zhou BY; Mao Q; Liu YH Genet Mol Res; 2012 Nov; 11(4):3933-41. PubMed ID: 22930430 [TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339 [TBL] [Abstract][Full Text] [Related]
27. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Collord G; Tarpey P; Kurbatova N; Martincorena I; Moran S; Castro M; Nagy T; Bignell G; Maura F; Young MD; Berna J; Tubio JMC; McMurran CE; Young AMH; Sanders M; Noorani I; Price SJ; Watts C; Leipnitz E; Kirsch M; Schackert G; Pearson D; Devadass A; Ram Z; Collins VP; Allinson K; Jenkinson MD; Zakaria R; Syed K; Hanemann CO; Dunn J; McDermott MW; Kirollos RW; Vassiliou GS; Esteller M; Behjati S; Brazma A; Santarius T; McDermott U Sci Rep; 2018 Sep; 8(1):13537. PubMed ID: 30202034 [TBL] [Abstract][Full Text] [Related]
28. The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value? Voß KM; Spille DC; Sauerland C; Suero Molina E; Brokinkel C; Paulus W; Stummer W; Holling M; Jeibmann A; Brokinkel B J Neurooncol; 2017 Jul; 133(3):641-651. PubMed ID: 28527009 [TBL] [Abstract][Full Text] [Related]
29. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240 [TBL] [Abstract][Full Text] [Related]
30. Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas. Sofela AA; Hilton DA; Ammoun S; Baiz D; Adams CL; Ercolano E; Jenkinson MD; Kurian KM; Teo M; Whitfield PC; Sahm F; Hanemann CO Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429944 [TBL] [Abstract][Full Text] [Related]
31. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival. Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286 [TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological Features of Meningiomas in Tibet]. Luo HH; Huo Z; Wang Q; NIma Z; Duo B; Wei Q; DA Z; Wang H; Guo PP; Liao RQ; CIren Q Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):621-627. PubMed ID: 36065695 [TBL] [Abstract][Full Text] [Related]
33. DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups. Singh J; Sharma R; Shukla N; Narwal P; Katiyar A; Mahajan S; Sahu S; Garg A; Sharma MC; Suri A; Sarkar C; Suri V J Neurooncol; 2023 Jan; 161(2):339-356. PubMed ID: 36564673 [TBL] [Abstract][Full Text] [Related]
34. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade. Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363 [TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center. Shan B; Zhang J; Song Y; Xu J Medicine (Baltimore); 2017 Jun; 96(26):e7385. PubMed ID: 28658170 [TBL] [Abstract][Full Text] [Related]
36. TERT Promoter Mutations and Risk of Recurrence in Meningioma. Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184 [TBL] [Abstract][Full Text] [Related]
37. Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen. Pizem J; Velnar T; Prestor B; Mlakar J; Popovic M Clin Neuropathol; 2014; 33(5):354-63. PubMed ID: 25034703 [TBL] [Abstract][Full Text] [Related]
38. Genetic changes with prognostic value in histologically benign meningiomas. Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303 [TBL] [Abstract][Full Text] [Related]
39. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression. Ke HL; Ke RH; Li ST; Li B; Lu HT; Wang XQ J Neurooncol; 2013 Jun; 113(2):327-32. PubMed ID: 23525949 [TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of multimodality management for parasagittal meningiomas. Hua L; Wang D; Zhu H; Deng J; Luan S; Chen H; Sun S; Tang H; Xie Q; Wakimoto H; Gong Y J Neurooncol; 2020 Apr; 147(2):441-450. PubMed ID: 32088814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]